Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5

Conclusion: This translational study identified CXCL5 as a biomarker of efficacy of lysosomotropic drugs, a potential asset for personalized medicine.

Source: Theranostics - June 13, 2019 Category: Molecular Biology Authors: Sandy Giuliano, Maeva Dufies, Papa Diogop Ndiaye, Julien Viotti, Delphine Borchiellini, Julien Parola, Val é rie Vial, Yann Cormerais, Micka ë l Ohanna, V é ronique Imbert, Emmanuel Chamorey, Nathalie Rioux-Leclercq, Ariel Savina, Jean-Marc Ferrero, Ba Tags: Research Paper Source Type: research